Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants
PharmaMar (MSE:PHM) has announced today the publication of an article in the Life Science Alliance journal, entitled "Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19," which includes a study on the in vitro activity of plitidepsin against the main SARS-CoV-2 variants, including the current Omicron variant.
PharmaMar signs a new licensing and commercialization agreement with Eczacibasi for lurbinectedin in Turkey
PharmaMar (MSE:PHM) has announced today a new license and commercialization agreement with the Eczacıbaşı Pharmaceuticals Marketing Co. to commercialize the anticancer drug lurbinectedin in Turkey.
PharmaMar appoints Lara Vadillo as Communication Director
PharmaMar (MSE:PHM) has appointed Lara Vadillo to lead the Company's Communication Department.
PharmaMar and Jazz Pharmaceuticals announce initiation of confirmatory phase III clinical trial of Zepzelca® (lurbinectedin) for the treatment of patients with relapsed Small Cell Lung Cancer
PharmaMar (MSE:PHM) and partner Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced the initiation of a confirmatory Phase III clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of patients with relapsed Small Cell Lung Cancer (SCLC).
PharmaMar launches its new corporate website
PharmaMar (MSE:PHM) has published today its new corporate website, with a revamped design and new functionalities. This new website represents what this company is today, a unique company with more than 30 years of successful history, three approved products and a promising future.
PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan
PharmaMar S.A. (MSE:PHM) has announced today a licensing agreement with Lotus Pharmaceutical CO., LTD. (TWSE:1795) to commercialize the anticancer drug lurbinectedin in Taiwan.